| Neuromyelitis optica spectrum disorders: still evolving and broadening |
27 |
| Multiple sclerosis: clinical aspects |
26 |
| Epidemiology of amyotrophic lateral sclerosis: an update of recent literature |
22 |
| Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis |
21 |
| Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy |
20 |
| Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm |
18 |
| Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment |
18 |
| Charcot-Marie-Tooth disease and related disorders: an evolving landscape |
18 |
| The changing course of multiple sclerosis: rising incidence, change in geographic distribution, disease course, and prognosis |
16 |
| Dystonia as a network disorder: a concept in evolution |
16 |
| The current place of epilepsy surgery |
16 |
| The changing landscape of motor neuron disease imaging: the transition from descriptive studies to precision clinical tools |
15 |
| Hereditary ataxias and paraparesias: clinical and genetic update |
15 |
| Advances in the understanding of headache in idiopathic intracranial hypertension |
14 |
| Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm |
14 |
| Autoimmune glial fibrillary acidic protein astrocytopathy |
14 |
| Update in Duchenne and Becker muscular dystrophy |
14 |
| The congenital myasthenic syndromes: expanding genetic and phenotypic spectrums and refining treatment strategies |
14 |
| Motor development and delay: advances in assessment of motor skills in autism spectrum disorders |
13 |
| Mechanisms for lesion localization in neuromyelitis optica spectrum disorders |
13 |
| Update on amyotrophic lateral sclerosis genetics |
13 |
| Neuroimaging in epilepsy |
12 |
| Cannabinoid therapy in epilepsy |
12 |
| Neurostimulation for drug-resistant epilepsy: a systematic review of clinical evidence for efficacy, safety, contraindications and predictors for response |
11 |
| Primary familial brain calcifications: genetic and clinical update |
11 |
| B cells in multiple sclerosis |
11 |
| GBA1-associated parkinsonism: new insights and therapeutic opportunities |
11 |
| Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults |
11 |
| Management of neurosarcoidosis: a clinical challenge |
11 |
| Vestibular rehabilitation: advances in peripheral and central vestibular disorders |
11 |
| Milestones in the development of a vestibular implant |
11 |
| Recent advances in headache neuroimaging |
11 |
| The patchy tremor landscape: recent advances in pathophysiology |
11 |
| Sex differences in neurodevelopmental disorders |
10 |
| Advance in genetics of migraine |
10 |
| Global orientation in space and the lateralization of brain functions |
10 |
| Posterior reversible encephalopathy syndrome |
10 |
| Update in therapeutic strategies for Parkinson's disease |
10 |
| The growing clinical spectrum of cerebral amyloid angiopathy |
10 |
| The impact of modern-day neuroimaging on the field of deep brain stimulation |
10 |
| Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis |
9 |
| Neurophysiological biomarkers in amyotrophic lateral sclerosis |
9 |
| MRI in epilepsy: clinical standard and evolution |
9 |
| The epileptic encephalopathy jungle - from Dr West to the concepts of aetiology-related and developmental encephalopathies |
9 |
| Pain in Parkinson's disease: new concepts in pathogenesis and treatment |
9 |
| The changing concepts in the neuropathology of acquired demyelinating central nervous system disorders |
9 |
| Therapeutic noninvasive brain stimulation in Alzheimer's disease and related dementias |
9 |
| Non-electroencephalography-based seizure detection |
9 |
| Spectrum of GABA(A) receptor variants in epilepsy |
9 |
| Risks and predictive biomarkers of sudden unexpected death in epilepsy patient |
9 |
